Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

December 1st, 2011

View Archives Issues

  • HIV/AIDS epidemic at 30 years: Promised land or wasteland?

    Thirty years after the world first became aware of a strange syndrome that caused young men to acquire rare diseases like Pneumocystis carinii pneumonia (PCP) and Kaposi's Sarcoma, nations across the globe continue to battle against the HIV/AIDS epidemic.
  • HIV prevention goal still elusive

    Researchers who have closely studied the United States' national HIV/AIDS prevention strategy as it has developed over the past three decades have concluded that it has been underfunded, and it's very difficult to implement.
  • Rethinking metrics used for goals

    One obstacle to the success of the U.S. national HIV/AIDS strategy involves the accuracy of metrics used for monitoring HIV care, including late diagnoses and linkage to sustained care, a new study notes.
  • Study looks at state disparities in HIV

    HIV/AIDS mortality data highlight disparities between states, suggesting differences in HIV treatment and care, a new study shows.1
  • AMA: Amend HIV transplant law

    The American Medical Association recently voted to support amending a federal law that bars clinical research of HIV-infected organ donation, as a potentially lifesaving measure for people living with HIV infection.
  • What's new in HIV treatment?

    A revision to the Jan. 10, 2011, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents was published on Oct. 14, 2011.
  • Abstract & Commentary: HIV-1 Protein linked to insulin resistance

    3T3L1 pre-adipocytes in cell culture were treated overnight with myristoylated or non-myristoylated recombinant Nef. Glucose uptake was measured with and without insulin stimulation.
  • FDA Notifications

    Updates to the darunavir (Prezista®) package insert, specifically sections: 6 Adverse Reactions, 12.4 Microbiology, 14 Clinical Studies and were approved on Oct. 19, 2011, to include results from the 192-week safety, resistance and efficacy data from study TMC114-C211, "A randomized, controlled, open-label Phase 3 trial comparing darunavir/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day (given as a twice daily or as a once daily regimen) in antiretroviral treatment-naïve HIV-1-infected adult subjects."